In loving memory of the late John Littler who sadly passed away on 15th October 2014.
John's funeral will take place at 1pm, Monday 3rd November, at Christ Church, Port Sunlight. Following the service close friends and family will attend John’s cremation at Blacon, Chester.
Please join the family at Wirral Postgraduate Centre, Clatterbridge Hospital, CH63 4JY, to share more memories of John after the service and for refreshments.
Donations in memory of John are kindly received for Radiotherapy Research, Clatterbridge Cancer Charity.
John’s ethos of offering optimum patient care meant that he was an avid supporter of constantly developing treatment techniques to improve treatment accuracy which would potentially lead to improved outcomes and reduced side effects.
John contributed significantly to the radiotherapy research and development program at CCC through his involvement in the development of image guided techniques for prostate patients using gold seed markers. He was also the lead clinician for respiratory gating for lung patients and taught this technique to centres throughout Europe at our teaching course on this subject.
John led the implementation of stereotactic body radiotherapy for lung patients at CCC, both at the early stage of the technique prior to image guidance being available on our treatment machine and subsequently following the establishment of the UK consortium he contributed to the national guidelines which is used across many centres benefitting many patients.
He provided support and encouragement to the multi-professional radiotherapy research and development team. He pushed for the utilisation of the CHART endowment fund to facilitate a 3 year research radiographer post which facilitated numerous other projects and the post holders gained valuable research skills which will stay with them throughout their careers.
John was quick to recognise the potential of functional imaging to aid the decision process for radiotherapy. He requested ventilation SPECT imaging for his lung patients where there was concern whether curative treatment could be tolerated. John was a key member of the group at CCC investigating how such functional information might be used to avoid toxicity to normal lung. A pilot study to investigate this clinically is now in preparation, funded by CCC charitable funds.
More recently John was very interested in using markers to track the position of lung tumours during treatment. We are developing a protocol for this using the Calypso ‘GPS’ system which we will be continuing over the coming months.